Testing effectiveness (Phase 2)Ended earlyNCT04433546
What this trial is testing
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
Who this might be right for
Acute Respiratory Distress SyndromeCoronavirusHypoxic Respiratory Failure+15 more
PhaseBio Pharmaceuticals Inc. 54